1,617 件 ・ 関連度順
概要と使いどころ
Sector overview, TAM estimation, competitive concentration HHI, regulatory landscape, industry analysis, market size analysis, sector trends, industry structure, market growth rate, sector profitability
日本語の概要は準備中です。原文の説明を表示しています。
DCF valuation model, discounted cash flow, intrinsic value, WACC calculation, terminal value, free cash flow projection, equity value per share, DCF sensitivity analysis, unlevered free cash flow, present value calculation, build a DCF
日本語の概要は準備中です。原文の説明を表示しています。
What-if scenario analysis, scenario tree construction, base bull bear case, sensitivity to macro variables, revenue scenario modeling, cost scenario analysis, margin impact scenarios, interest rate sensitivity, currency impact scenarios, commodity price scenarios
日本語の概要は準備中です。原文の説明を表示しています。
Weekly clinical-trial status diff — the 11-category change report over the stored weekly snapshots (spec 055 FR-B03). Surfaces exactly what changed on the trial registry for your coverage: New / Suspended / Withdrawn / Terminated / Recruiting / Recruitment-Complete / Completed / Ahead / Delayed / Upsized / Downsized, every row carrying previous and new values, with risk flags on Terminated and Downsized and re-timing flags on Ahead and Delayed. The stored-previous-value discipline makes each week's diff reproducible.
日本語の概要は準備中です。原文の説明を表示しています。
Earnings sentiment analysis, analyst estimates vs guidance, earnings surprise history, consensus sentiment, earnings revision trends, analyst rating changes, earnings beat miss track record, guidance accuracy, whisper numbers, pre-announcement sentiment
日本語の概要は準備中です。原文の説明を表示しています。
Device pipeline analysis: feasibility and pivotal study stages, design-iteration cycles, RWE studies, and post-market obligations, with reimbursement-aware value framing and decision-track awareness across the med universe.
日本語の概要は準備中です。原文の説明を表示しています。
Business model classification, business model analysis, structural analysis of how a company makes money, product offering decomposition, distribution channel analysis, customer segment analysis, revenue model identification, market sizing TAM SAM SOM, competitive positioning, business unit performance, management team & leadership analysis, what does the company sell, how does the company go to market, business model type platform service product, channel mix direct vs indirect, revenue concentration risk, CEO CFO executive backgrounds and changes
日本語の概要は準備中です。原文の説明を表示しています。
Interest rate cycle analysis, Fed policy analysis, yield curve dynamics, duration management, central bank rate trajectory, monetary tightening easing, bond market analysis, rate forecast, forward curve, dot plot interpretation, rate hike cut cycle
日本語の概要は準備中です。原文の説明を表示しています。
Macro-driven trade idea generation, translating macroeconomic views into concrete stock ideas, sector selection from macro regime, international trade ideas via ADRs, cross-border idea sourcing, macro catalyst mapping to equity positions
日本語の概要は準備中です。原文の説明を表示しています。
Investment pitch deck, investment committee presentation, buy-side pitch, sell-side pitch, investment thesis slides, executive summary presentation, financial presentation, board deck, investor presentation, strategy deck
日本語の概要は準備中です。原文の説明を表示しています。
Leading economic indicators analysis, ISM PMI, yield curve, consumer sentiment UMCSI, jobless claims, building permits, economic turning point detection, recession signal analysis
日本語の概要は準備中です。原文の説明を表示しています。
Med-adapted recent-quarter review: last print financials, pipeline-milestone awareness, and FDA-event context — reads the quarter through the med lens (milestones moved, runway, regulatory updates) rather than generic financials alone.
日本語の概要は準備中です。原文の説明を表示しています。
Device-track catalyst analysis: 510(k), PMA, and De Novo decision events, CMS coverage and NTAP milestones, recalls and watch actions as risk signals, and post-market surveillance obligations — dated, verified, and sized per event for any medtech ticker or watchlist.
日本語の概要は準備中です。原文の説明を表示しています。
CDER-track catalyst analysis for medicines: PDUFA target dates, AdCom votes, sNDA/sBLA label expansions, biosimilar interchangeability and 180-day exclusivity, Orange Book state, and CRL remediation timelines — enumerated, verified, and sized per event for any biotech/pharma ticker or watchlist.
日本語の概要は準備中です。原文の説明を表示しています。
Recent quarter performance analysis, quarterly earnings review, last quarter results, quarterly financial performance, analyze recent quarter, Q4 earnings, quarterly revenue breakdown, EPS this quarter, margin analysis recent quarter, sequential growth, quarterly performance review
日本語の概要は準備中です。原文の説明を表示しています。
Medicines pipeline analysis over structured universes: Phase I-III assets with probability-of-success discipline (unadjusted peak x POS = modeled value; POS changes logged with reasons), trial status-diff tracking, and mechanism/competitor mapping via drug-knowledge lookups.
日本語の概要は準備中です。原文の説明を表示しています。
LBO model, leveraged buyout, private equity acquisition, sources and uses, debt schedule, returns waterfall, sponsor IRR, MOIC calculation, PE exit analysis, LBO valuation
日本語の概要は準備中です。原文の説明を表示しています。
Growth strategy analysis, organic growth decomposition, inorganic growth, M&A strategy, pipeline analysis, revenue growth drivers, strategic initiatives, expansion strategy, growth trajectory, product pipeline growth
日本語の概要は準備中です。原文の説明を表示しています。
Post-event analyst note (conferences, KOL events, site visits) with the professional note anatomy — headline verdict, per-stock takeaways with model numbers, KOL distillation, cross-trial comparison lattices, modeled deltas vs consensus (peak × POS), three what's-changed vectors, risk bullets, and materiality-rated conflicting views. Use after any med event to convert the event into actionable takeaways.
日本語の概要は準備中です。原文の説明を表示しています。
Vaccine catalyst analysis across the two-gate path: CBER BLA review and the ACIP recommendation gate that turns FDA approval into commercial availability. Lot release, procurement milestones, pediatric bridging, and healthy-population efficacy context — dated, verified, and sized per event.
日本語の概要は準備中です。原文の説明を表示しています。
Macro regime analysis, bull bear market detection, business cycle analysis, macro environment assessment, interest rate cycle, yield curve analysis, monetary policy, fiscal policy, global macro, central bank posture, credit cycle, recession probability, expansion regime, macro regime shift, stagflation detection
日本語の概要は準備中です。原文の説明を表示しています。
Competitive positioning, strategic group mapping, differentiation analysis, competitive advantage assessment, market positioning map, value chain positioning, brand positioning, cost leadership vs differentiation, niche strategy analysis, disruptive positioning
日本語の概要は準備中です。原文の説明を表示しています。
Weekly product-level commercial tracking — TRx/NRx with current/4-wk/12-wk share and YoY, launch curves overlaid with same-class analogs plus a consensus-implied trajectory, LOE/biosimilar erosion series, GTN/net-price stress brackets, and per-row data-caveat discipline. Use to track any launched drug, biologic, device, or vaccine against its class and consensus.
日本語の概要は準備中です。原文の説明を表示しています。
Operational KPI tracking, headcount trends, utilization rates, backlog analysis, book-to-bill ratio, operational efficiency metrics, capacity utilization, productivity metrics, operational leverage, same-store sales
日本語の概要は準備中です。原文の説明を表示しています。